MedTrace Logo

Ranolazine in Ischemic Cardiomyopathy

NCT01345188 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-12-09

Study results available
· View outcomes & findings →

Summary

Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.

Conditions

Interventions

DRUG

Ranexa

1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

DRUG

Placebo

1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Midwest Cardiovascular Research Foundation

    lead OTHER

Principal Investigators

  • Nicolas W Shammas, MD · Midwest Cardiovascular Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01345188 on ClinicalTrials.gov